Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hitomi Sakai"'
Autor:
Keiji Furuuchi, Toshimitsu Uenaka, Ryoji Kato, Hitomi Sakai, Yuta Onodera, Elizabeth B. Somers, Hisato Kawakami, Takeshi Teramura, Kazuhiko Nakagawa
Publikováno v:
Clinical and Translational Medicine
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Clinical and Translational Medicine, Vol 11, Iss 6, Pp n/a-n/a (2021)
Background The main function of folate receptor α (FOLRα) has been considered to mediate intracellular folate uptake and induce tumor cell proliferation. Given the broad spectrum of expression among malignant tumors, including gastric cancer (GC) b
Autor:
Miki Nakura, Hitomi Sakai, Miyuki Endo, Kazuhiko Nakagawa, Atsuko Koyama, Kaoru Tanaka, Toshiko Yasuda, Satomi Watanabe, Makiko Hayashi
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 16
PURPOSE Cancer treatment can alter patient appearance, leading to psychological, social, and behavioral issues. This study aimed to investigate distress and difficulties related to appearance concerns in Japanese cancer patients and to identify infor
Autor:
Koji Haratani, Yasutaka Chiba, Shiki Takamura, Takafumi Okabe, Kenji Hirotani, Hiroyasu Kaneda, Michiko Yamato, Kaoru Tanaka, Shigeki Kato, Kazuhiko Nakagawa, Kazuto Nishio, Hidetoshi Hayashi, Yoshikazu Hasegawa, Masayuki Takeda, Kazuko Sakai, Kimio Yonesaka, Masaaki Miyazawa, Osamu Maenishi, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Hitomi Sakai, Keita Kudo
Publikováno v:
Clinical Cancer Research. 24:2653-2664
Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed
Autor:
Junji Tsurutani, Kazuhiko Nakagawa, Kazuko Sakai, Hitomi Sakai, Tsutomu Iwasa, Kazuto Nishio, Yoshifumi Komoike
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Trastuzumab emtansine (T-DM1) is approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), and has high efficacy. However, some patients exhibit primary resistance to
Publikováno v:
Japanese Journal of Clinical Oncology. 47:611-617
Purpose The Institute of Medicine (IOM) of the United States recommends that all cancer survivors be provided with a survivorship care plan (SCP), which includes a patient treatment summary and a follow-up care plan. However, SCPs have not been widel
Publikováno v:
Mol Clin Oncol
Anorectal melanoma is a rare disease with a poor prognosis and its response to immunotherapy remains poorly studied. The current study reports a case of recurrent anorectal melanoma in a 60-year-old woman that has exhibited a durable response to ipil
Publikováno v:
Journal of Clinical Oncology. 33:e20601-e20601
e20601 Background: Many people seek a second opinion to hear different opinions on the best treatment options and to learn more about the cancer. There are few reports on second-opinion seeking in ...
Publikováno v:
BMC Cancer
Background This analysis was undertaken to evaluate the practice patterns of Japanese physicians regarding curative-intent chemotherapy, especially in outpatient settings, and to define factors negatively affecting the maintenance of relative dose in